Seattle Genetics (SGEN) Misses Q2 EPS by 12c, Offers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Seattle Genetics Reports Second Quarter 2015 Financial Results
July 30, 2015 4:02 PM EDT-Total Second Quarter 2015 Revenues of $77.1 Million, Including Record $55.1 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales-
-ADCETRIS 2015 Net Sales Guidance Increased to a Range of $210 Million to $220 Million-
-Potential ADCETRIS Label Expansion through AETHERA Supplemental Biologics License Application (BLA) Currently Under FDA Priority Review; PDUFA Action Date August 18, 2015-
-Additional Clinical Data from Multiple Pipeline Programs Expected In Next Six to Nine Months, Including SGN-CD33A for Acute Myeloid Leukemia-
-Conference Call Today at 4:30 p.m. ET-... More
